Ocumetics Reports Positive Three Month First-in-Human Results, Significantly De-Risking Its Accommodating Intraocular Lens Technology
Executive Summary
- Ocumetics Technology Corp. reported positive three‑month postoperative results from Group 1 of its first‑in‑human (FIH) study of the Ocumetics Accommodating Intraocular Lens, meeting or exceeding all safety, delivery and visual performance benchmarks.
- The data de‑risk the core technology, validating the platform and clearing a key milestone toward subsequent clinical phases (Group 2).
- Management expressed full confidence in the lens technology and announced that refinements are already underway for Group 2 surgeries, with manufacturing of optimized lenses in progress.
Key Details
- Study Outcomes – Group 1:
- Safety profile met predefined expectations.
- Visual acuity outcomes met and exceeded internal benchmarks; patients with pre‑operative acuities as poor as 20/250 achieved meaningful vision improvements.
-
Lens delivery system performed within expected parameters.
-
Patient Impact:
-
Participants moved from legal blindness to being able to read, drive, and perform daily activities, according to principal investigator Dr. Rafael Vázquez.
-
Clinical Milestone:
-
Successful validation of the core accommodating intraocular lens technology; primary objectives for Phase 1 achieved, enabling progression to Group 2.
-
Forward Path:
- Refinements to the lens delivery mechanism already implemented based on surgeon feedback.
- Manufacturing and testing of optimized lens designs are underway.
-
Group 2 surgeries will be scheduled after final lens validation is completed.
-
Management Commentary:
-
Dean Burns, President & CEO, stated he is “100% confident” in the technology and highlighted the milestone’s material strengthening of the clinical foundation.
-
Upcoming Webinar:
- Date: Wednesday, February 4 2026, 4:00 PM ET – hosted by Dean Burns to discuss study results and next steps.
Notable Quotes
“These first‑in‑human results are exactly what we were aiming to demonstrate at this stage: safe implantation, reliable delivery, and strong visual outcomes.” – Dean Burns, President & CEO, Ocumetics
“The impact on their independence and sense of freedom has been remarkable.” – Dr. Rafael Vázquez, Principal Investigator
Materiality Assessment: Material – Positive (the release provides substantive clinical validation that materially de‑risks the company’s core product and supports future development milestones).